Non-Executive Board Member
Vanessa King is a Venture Partner at Abingworth, LLP. Prior to this, she was Chief Executive Officer of Cadent Therapeutics, where she led its transformation into a precision medicine neuroscience company with a clinical pipeline. Before that, Vanessa was Vice President Business Development at deCODE Genetics, yielding its acquisition by Amgen in 2012 for USD 415 million.
She has also served as Executive Chairman of Tiaki Therapeutics, been an Entrepreneur in Residence at Atlas Venture, and held senior business development and operating positions at Amgen and Novartis.
Vanessa received a PhD in Molecular Genetics from the University of Cambridge.